SMARCA4-deficient non-small cell lung cancer and immunotherapy resistance: mechanisms and novel strategies-a mini-review - PubMed
8 hours ago
- #SMARCA4-deficient NSCLC
- #Combination therapy
- #Immunotherapy resistance
- SMARCA4-deficient non-small cell lung cancer (NSCLC) is associated with immunotherapy resistance.
- The review discusses mechanisms behind immunotherapy resistance in SMARCA4-deficient thoracic tumors.
- Novel therapeutic strategies, including combination therapies, are explored to overcome resistance.
- The tumor microenvironment plays a critical role in the response to immune checkpoint inhibitors.
- Recent studies highlight the need for further research into SMARCA4-deficient NSCLC treatment options.